The HER2 status of the primary gastric adenocarcinomas was scored as 0 in 29 specimens (64.4%), 1+ in seven (15.6%), 2+ in seven (15.6%), and 3+ in two (4.4%), while CB-MEs were scored as 0 in 35 specimens (77.8%), 1+ in six (13.3%), 2+ in one (2.2%), and 3+ in three (6.7%). This evidence concerns the gene ERBB2 and gastric adenocarcinoma.